Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 2,065 |
|
|||||
| News | - | ||||||
| Day High | 0.10 | Low High |
|||||
| Day Low | 0.08 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| IntelliPharmaCeutics International Inc (QB) | IPCIF | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.04 | 66.67% | 0.10 | 15:00:05 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.08 | 0.08 | 0.10 | 0.10 | 0.06 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4 | 2,065 | US$ 0.09 | US$ 186 | - | 0.0012 - 0.135 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:50:00 | 1,000 | US$ 0.10 | USD |
IntelliPharmaCeutics International Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 3.26M | 32.62M | 32.51M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
IntelliPharmaCeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/07/2024 | 14:21 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
| 2/14/2024 | 13:48 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 10/16/2023 | 16:23 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
| 10/06/2023 | 10:33 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
| 10/06/2023 | 10:33 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
| 9/26/2023 | 16:29 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
| 9/26/2023 | 16:23 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPCIF Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.06 | 0.10 | 0.06 | 0.06 | 351 | 0.04 | 66.67% |
| 1 Month | 0.06 | 0.135 | 0.06 | 0.0693985 | 13,863 | 0.04 | 66.67% |
| 3 Months | 0.0579 | 0.135 | 0.0255 | 0.0671487 | 10,771 | 0.0421 | 72.71% |
| 6 Months | 0.06 | 0.135 | 0.0255 | 0.0648088 | 11,964 | 0.04 | 66.67% |
| 1 Year | 0.0178 | 0.135 | 0.0012 | 0.0660368 | 12,123 | 0.0822 | 461.80% |
| 3 Years | 0.21 | 0.2998 | 0.0012 | 0.1113711 | 11,661 | -0.11 | -52.38% |
| 5 Years | 0.18995 | 1.50 | 0.0012 | 0.3139286 | 59,132 | -0.08995 | -47.35% |
IntelliPharmaCeutics (QB) Description
| Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company's abuse-deterrent oxycodone hydrochloride extended release formulation ("Oxycodone ER") based on its proprietary nPODDDS novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). |
